The study determined that CAF suppression of CD8+ and promotion of FoxP3+ tumor-infiltrating lymphocytes was mediated by IL-6, suggesting IL-6 blockade via CAF targeting as a possibility to enhance the efficacy of immunotherapy in esophageal cancers. Here, FOXP3 is linked to neoplasm.